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hat Is the Risk of Stent Thrombosis
ssociated With the Use of Paclitaxel-Eluting
tents for Percutaneous Coronary Intervention?
Meta-Analysis
nthony A. Bavry, MD, MPH,* Dharam J. Kumbhani, MD, SM,† Thomas J. Helton, DO,*
eepak L. Bhatt, MD*
leveland, Ohio; and Boston, Massachusetts
OBJECTIVES This study investigated the risk of stent thrombosis associated with the use of paclitaxel-
eluting stents (PES) compared to bare-metal stents (BMS).
BACKGROUND Clinical experience with coronary drug-eluting stents (DES) is relatively limited. There is
concern that DES used for percutaneous coronary intervention may result in subsequent
thrombosis.
METHODS We conducted a meta-analysis on eight trials (total of 13 study arms) in 3,817 patients with
coronary artery disease who were randomized to either PES or BMS.
RESULTS As compared with BMS, PES do not increase the hazard for thrombosis up to 12 months
(risk ratio [RR]  1.06, 95% confidence interval [CI] 0.55 to 2.04, p  0.86]). There was no
evidence of heterogeneity among the studies (chi-square value for Q-statistic  5.90 [10
degrees of freedom], p 0.82). Similar results were obtained when the analysis was restricted
to trials with a polymeric stent platform (Treatment of de novo coronary disease using a single
pAclitaXel elUting Stent [TAXUS]-I, -II, -IV, and -VI) (RR  1.01, 95% CI 0.40 to 2.53,
p  0.99), trials with longer lesions (TAXUS-IV and -VI) (RR  0.62, 95% CI 0.2 to 1.91,
p  0.41), and trials that used a higher dose of paclitaxel (ASian Paclitaxel-Eluting Stent
Clinical trial [ASPECT], European evaLUaTion of paclitaxel Eluting Stents [ELUTES],
and DELIVER-I) (RR  1.87, 95% CI 0.52 to 6.81, p  0.34).
CONCLUSIONS Current evidence suggests that standard dose PES do not increase the hazard of stent
thrombosis compared to BMS. (J Am Coll Cardiol 2005;45:941–6) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.11.064American College of Cardiology Foundation
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tercutaneous coronary intervention (PCI) is often limited
y restenosis. The advent of drug-eluting stents (DES)
enerated excitement by dramatically reducing restenosis
1,2). A pooled analysis documented a 74% reduction in the
isk of target-lesion revascularization from the use of
irolimus-eluting stents (Cypher, Johnson & Johnson, Mi-
mi Lakes, Florida) or paclitaxel-eluting stents (PES)
TAXUS, Boston Scientific Corp., Natick, Massachusetts)
ompared to bare-metal stents (BMS) (3).
Based on a number of clinical case reports, concerns have
een raised about an increased risk of stent thrombosis with
ES. This prompted the release of an advisory concerning
potential risk of subacute thrombosis and hypersensitivity
eactions with the use of sirolimus-eluting stents (4). It is
ossible that with increased use and experience with PES,
imilar concerns may surface. Accordingly, we conducted a
ystematic review of the literature specific to PES to study
From the *Department of Cardiovascular Medicine, Cleveland Clinic Foundation,
leveland, Ohio; and the †Department of Cardiac Surgery, Veterans Administration
oston Healthcare System, Brigham and Women’s Hospital, Harvard Medical
chool, Boston, Massachusetts.a
Manuscript received August 3, 2004; revised manuscript received November 11,
004, accepted November 29, 2004.he association between this stent and the risk of thrombosis
fter PCI.
ETHODS
iterature review. We searched the MEDLINE, EM-
ASE, CRISP, metaRegister of Controlled Trials, and
ochrane databases for randomized clinical trials from 2001
o 2004 using the medical subject heading terms “angio-
lasty, transluminal, percutaneous coronary,” “stents,” “pac-
itaxel,” and “thrombosis.” We also hand-searched relevant
ournals, obtained recently presented data from national
ardiology and interventional cardiology conferences, corre-
ponded with authors and experts in the field, and used the
cience Citation Index to cross-reference any articles that
et our selection criteria.
Our inclusion criteria were as follows: 1) a randomized
linical trial that assigned patients to either a PES or BMS;
nd 2) angiographically documented thrombosis data were
vailable for at least 30 days of follow-up. Stent thrombosis
as defined as either an angiographically documented
hrombosis or an event where angiographic data were not
vailable, although the study investigators clinically pre-
s
e
s
o
e
(
p
A
E
[
T
T
T
a
D
t
a
b
i
t
a
c
r
d
u
E
s
m
a
a
d
t
n
v
t
a
d
a
l
D
t
S
b
s
o
c
h
p
r
c
c
w
e
P
c
w
l
S
T
R
B
i
P
T
t
i
t
d
s
y
t
p
H
f
Q
S
(
R
u
o
s
s
E
a
n
A
E
s
i
a
t
i
a
p
r

t
942 Bavry et al. JACC Vol. 45, No. 6, 2005
Paclitaxel-Eluting Stent Thrombosis March 15, 2005:941–6umed that a stent thrombosis occurred. Studies were
xcluded from analysis if both groups received DES, if
irolimus (rapamycin) was used, if paclitaxel was given
rally, if other analogues of paclitaxel such as QP-2 were
mployed, or if reliable data could not be obtained.
We identified eight studies that compared PES to BMS
Treatment of de novo coronary disease using a single
AclitaXel elUting Stent [TAXUS]-I, -II, -IV, and -VI,
Sian Paclitaxel-Eluting Stent Clinical trial [ASPECT],
uropean evaLUaTion of paclitaxel Eluting Stents
ELUTES], DELIVER-I, and PAclitaxel-Coated logics
ENt for the CYtostatic prevention of restenosis [PA-
ENCY]) (5–16). This represents 13 study arms as
AXUS-II had two DES arms, ASPECT had two arms,
nd ELUTES had four arms.
ata abstraction. Two independent reviewers abstracted
he following outcomes by intention-to-treat analysis: 1)
ngiographically documented or presumed coronary throm-
osis; and 2) length of follow-up from deployment of the
ndex stent procedure. We also abstracted baseline informa-
ion such as patient demographics as well as angiographic
nd procedural characteristics of the coronary artery revas-
ularization. Discrepancies were resolved through a third
eviewer. Because all eight studies were double-blind ran-
omized clinical trials, a formal quality assessment was not
sed.
nd points. In order to utilize data from all available
tudies, and thereby increase the statistical power of our
eta-analysis, we considered stent-associated thrombosis at
ny point in time (up to one year) after the index procedure
s the primary end point. In trials that examined various
oses or release kinetics of paclitaxel, each DES arm was
reated as a separate study for analysis. We also conducted a
umber of subanalyses by analyzing groups that shared
arious similarities. The four TAXUS trials were analyzed
ogether because they used clopidogrel for six months in
ddition to aspirin, while the other four trials used a shorter
uration of dual antiplatelet therapy. Similarly TAXUS-IV
nd -VI trials studied patients with longer lesions (mean
ength 12 mm), while ASPECT, ELUTES, and
ELIVER-I trials examined higher doses of paclitaxel (2.7
o 3.1 g/mm2) and were analyzed together.
tatistical methods. We tabulated the number of throm-
oses and persons at risk for thrombosis in each arm of a
tudy and calculated the risk ratio (RR) (PES vs. BMS). In
rder to determine if the studies were similar enough to be
Abbreviations and Acronyms
BMS  bare-metal stents
CI  confidence interval
DES  drug-eluting stents
PCI  percutaneous coronary intervention
PES  paclitaxel-eluting stents
RR  risk ratioomparable for analysis, the Cochran’s Q statistic for deterogeneity was employed. To evaluate if the studies were
ublished with a certain bias (i.e., only studies with positive
esults were published), the Egger’s funnel plot for publi-
ation bias was constructed. We utilized the automatic “zero
ell” correction so that studies with no events in a single arm
ould still be included for analysis. We obtained a summary
stimate of the RR and 95% confidence interval (CI) for
ES compared to BMS. A fixed effects model was used to
alculate the summary statistic. All p values were two-tailed,
ith statistical significance set at 0.05. All CIs were calcu-
ated at the 95% level. All analyses were performed using
TATA software v8.0. (STATA Corp., College Station,
exas).
ESULTS
aseline characteristics. The eight studies that met our
nclusion criteria were TAXUS-I, -II, -V, and -VI, AS-
ECT, ELUTES, DELIVER-I, and PATENCY (5–16).
he characteristics of these studies are listed in Table 1. A
otal of 3,817 patients were enrolled; 1,995 were random-
zed to PES and 1,822 to BMS. All trials were multicen-
ered studies. The baseline characteristics of patients ran-
omized to PES and to BMS were similar within each
tudy. The median ages of participants ranged from 58 to 66
ears. The percentage of enrolled females ranged from 6%
o 38%. Approximately one-quarter to one-third of the
atients had a history of previous myocardial infarction.
eterogeneity/publication bias. There was no evidence
or heterogeneity among the studies (chi-square value for
-statistic  5.90 [10 degrees of freedom], p  0.82).
imilarly the p value for publication bias was nonsignificant
p  0.86).
isk of stent-associated thrombosis. Length of follow-
p, event data, and RRs (with 95% CI) for the development
f stent-associated thrombosis are listed in Table 2. Six
tudy arms revealed a nonsignificant decrease in the risk of
tent-associated thrombosis (TAXUS-IV, TAXUS-VI,
LUTES: 0.2, 0.7, and 1.4 g paclitaxel/mm2 of stent
rms; and DELIVER-I), five study arms revealed a nonsig-
ificant increase in risk (TAXUS-II SR and MR arms and
SPECT: 1.3 and 3.1 g paclitaxel/mm2 of stent arms, and
LUTES 2.7 g paclitaxel/mm2 of stent arm), and in two
tudies there were no events (TAXUS-I and PATENCY).
In the ASPECT trial, all cases of thrombosis occurred in
ndividuals randomized to PES who received nontraditional
ntiplatelet therapy (i.e., aspirin without the use of a
hienopyridine). Aspirin and cilostazol was used in these
ndividuals for one month (n  29) or six months (n  8)
s this was considered standard antiplatelet therapy at the
articipating centers. The remaining individuals in this trial
eceived aspirin with ticlopidine (n  120) or clopidogrel (n
18) for one or six months. The duration of therapy for
hose that received clopidogrel was one month, while the
uration of therapy for 78% of the individuals given ticlo-
Table 1. Baseline Characteristics of Eight Paclitaxel-Eluting Stent Studies
Characteristic TAXUS-I TAXUS-II* TAXUS-IV TAXUS-VI ASPECT† ELUTES‡ DELIVER-I PATENCY
Demographic characteristics
Primary site Germany Europe U.S. Europe Asia Europe U.S. U.S.
Total no. of patients
DES 31 266 662 219 118 153 522 24
BMS 30 270 652 227 59 39 519 26
Age (median yrs)
DES 66 60 63 62 59 60 62 66 (overall)
BMS 64 60 62 63 58 61 63
Men (%)
DES 94 73 72 76 76 82 71 67
BMS 83 78 72 76 76 82 71 62
Diabetes (%)
DES 23 14 23 18 21 17 31 25
BMS 13 15 25 22 17 10 29 23
Current smokers (%)
DES 54 23 23 NA 44 36 25 NA
BMS 47 27 20 46 33 25
Previous MI (%)
DES 26 38 31 43 23 33 26 NA
BMS 30 43 30 42 29 41 27
Angiographic and procedural characteristics
Use of GP IIb/IIIa inhibitors (%)
DES NA 16 58 21 NA 31 (overall) 64 NA
BMS 18 57 19 64
Target coronary artery—LAD/RCA/CX (%)
DES 55/23/23 41/35/24 40/31/29 53/29/18 51/24/23 38/27/21 42/34/23 40/28/32
BMS 27/37/37 48/37/16 41/32/27 47/34/19 51/29/20 38/28/23 47/23/30 (overall)
AHA/ACC lesion class, A/B1/B2/C (%)
DES 32/39/29/0 NA NA 1/35/63/1 54/40/4/1 NA 17/42/33/8 NA
BMS 13/43/43/0 0/35/64/1 51/41/8/0 20/42/35/4
Diameter of reference vessel (mm)
DES 2.99 2.75 2.75 2.82 2.93 2.95 2.85 2.77
BMS 2.94 2.75 2.75 2.77 2.88 2.99 2.77 3.01
Length of lesion (mm)
DES 10.7 10.4 13.4 21.0 11.0 10.8 11.7 25 (overall)
BMS 11.9 10.6 13.4 20.3 10.5 10.8 11.1
Dose of paclitaxel used (g/mm2 of stent) 1.0 1.0 1.0 1.0 1.3 and 3.1 0.2, 0.7, 1.4, and 2.7 3.0 2.0
Stent used§
DES TAXUS-SR TAXUS-SR/MR TAXUS-SR TAXUS-MR Supra-G non-polymeric V-flex Plus non-polymeric ACHIEVE LOGIC PTX
BMS NIRx NIRx EXPRESS EXPRESS Supra-G V-flex Plus ML PENTA LOGIC
*TAXUS-II had two stent arms with different release kinetics. Participants received either a slow release stent (TAXUS-SR) or a moderate release stent (TAXUS-MR). Each group had its own control. Data presented here are pooled
from both SR and MR arms. †ASPECT had two stent arms with different dose densities. Participants received either 1.3 or 3.1 g paclitaxel/mm2 of stent. There was one control arm. Data presented here are weighted averages from
both dose density arms. Data from the 3.1 g paclitaxel/mm2 of stent arm was used for subanalysis. ‡ELUTES had four stent arms with different dose densities. Participants received either 0.2, 0.7, 1.4 or 2.7 g paclitaxel/mm2 of stent.
There was one control arm. Data presented here are weighted averages from all dose density arms. Data from the 2.7 g paclitaxel/mm2 was used for subanalysis. §Manufacturers of paclitaxel eluting stents: TAXUS/NIRx/EXPRESS-
Boston Scientific, Supra-G/V-Flex/LOGIC PTX-Cook Inc., RX ACHIEVE/ML PENTA-Cook Inc./Guidant Corp. Only the TAXUS stents are polymeric, the others are non-polymeric stents.
BMS bare-metal stent; DES drug-eluting stent; GP glycoprotein; LAD/RCA/CX left anterior descending artery, right coronary artery, and circumflex artery, respectively; MImyocardial infarction; MRmoderate-release;
NA  data not available; SR  slow-release.
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Paclitaxel-Eluting Stent Thrombosis March 15, 2005:941–6idine was six months (one month of therapy for the
emaining individuals on ticlopidine).
The plot of stent-associated thrombosis and the pooled
R estimate is shown in Figure 1. The hazard of stent
hrombosis for PES versus BMS was not increased up to 12
onths after the index stent deployment (RR  1.06, 95%
I 0.55 to 2.04, p  0.86).
ubanalyses. When the four TAXUS trials that used
spirin and clopidogrel for six months were analyzed to-
ether, the summary RR obtained was similar to the overall
ffect estimate (RR 1.01, 95% CI 0.40 to 2.53, p 0.99).
nalyzing TAXUS-IV and -VI, which enrolled patients
ith longer lesions (mean length 12 mm) resulted in a
imilar association (RR  0.62, 95% CI 0.20 to 1.91, p 
.41). Analyzing ASPECT, ELUTES, and DELIVER-1,
hich used a higher dose of paclitaxel (approximately 3.0
g/mm2) revealed the same overall association (RR  1.87,
5% CI 0.52 to 6.81, p  0.34).
Table 2. Event Data and Outcome Measures
Trial Name Follow-Up
D
Thro
TAXUS-I 12 months 0/
TAXUS-II (SR) 12 months 2/
TAXUS-II (MR) 12 months 1/
TAXUS-IV 12 months 4/
TAXUS-VI 9 months 1/
ASPECT (1.3) 6 months 1/
ASPECT (3.1) 6 months 3/
ELUTES (0.2) 12 months 0/
ELUTES (0.7) 12 months 0/
ELUTES (1.4) 12 months 0/
ELUTES (2.7) 12 months 1/
DELIVER-I 12 months 2/
PATENCY 9 months 0/
Numbers within parentheses in trial name column represent
CI  confidence interval.
igure 1. In trials with varying doses of paclitaxel, a  1.3, b  3.1, A 
.2, B  0.7, C  1.4, and D  2.7 g paclitaxel/mm2 of stent. BMS m
are-metal stent; CI  confidence interval; DES  drug-eluting stent;
R  moderate-release; SR  slow-release.ISCUSSION
ur meta-analysis suggests that stent-associated thrombosis
s not increased by standard-dose PES compared to BMS.
n fact, the risk of stent-associated thrombosis up to 12
onths after the index procedure was equivalent with PES
ompared to BMS. This information is derived from sys-
ematically analyzing eight worldwide clinical trials that
ave been published or presented at prominent cardiology
onferences to date.
We performed various subanalyses. These examined the
ffect of longer duration of dual antiplatelet therapy (in
ontrast to shorter duration of therapy), longer versus
horter lesion lengths, and higher versus lower doses of
aclitaxel (around 3 g/mm2). The subanalyses confirmed
he same overall association of no increased (or decreased)
isk of stent-associated thrombosis. It should be noted that
lthough there was a nonsignificant increased risk of stent-
ssociated thrombosis with higher doses of paclitaxel, this
ssociation was driven by a high rate of stent thrombosis in
he ASPECT trial.
It is interesting that all thrombotic events in the AS-
ECT trial occurred in participants randomized to PES
ho were on aspirin and cilostazol. No events occurred in
ither stent group when standard antiplatelet therapy (aspi-
in with a thienopyridine) was employed. The TAXUS
tudies used clopidogrel for six months after the index stent
eployment, while ELUTES, DELIVER-I, and PA-
ENCY used clopidogrel for three months. This suggests
hat a nonthienopyridine-based antiplatelet regimen is not
ufficient in preventing thrombosis, and this issue may be
specially important for DES (17).
We did not formally analyze the Stent Comparative
Estenosis (SCORE) trial because this study used a pacli-
axel analogue (7-hexanoyltaxol) that could not be directly
ompared to PES (18). This trial was terminated early
econdary to a high rate of stent thrombosis (9.4%) and
is
BMS
Thrombosis
Risk Ratio
(95% CI)
0/30 —
0/136 5.11 (0.25, 105.49)
0/134 2.96 (0.12, 71.93)
5/652 0.79 (0.21, 2.93)
3/227 0.35 (0.04, 3.32)
0/59 3.00 (0.12, 72.18)
0/59 6.56 (0.35, 124.41)
1/39 0.36 (0.02, 8.56)
1/39 0.33 (0.01, 7.95)
1/39 0.34 (0.01, 8.14)
1/39 1.05 (0.07, 16.24)
2/519 0.99 (0.14, 7.03)
0/26 —
of paclitaxel in g/mm2 of stent.ES
mbos
31
131
135
662
219
58
60
37
40
39
37
522
24yocardial infarction (14.5%). This event rate occurred
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March 15, 2005:941–6 Paclitaxel-Eluting Stent Thrombosisespite the use of aspirin plus a thienopyridine for 1 month
n the BMS arm and for 12 months in the DES arm.
The current study is limited in that some of the analyzed
rials had small sample size, with relatively short duration of
ollow-up. We also included data that have only been
eported in conference presentations or in abstract form and
o have not undergone peer review. This was necessary,
owever, to maximize the utilization of all available data on
his rapidly evolving topic. Experience with coronary stents
as elucidated several predictors of stent thrombosis includ-
ng residual dissection, underexpansion of the stent, com-
ining/overlapping different stents, and longer total stent
ength (19–22). Based on the randomized nature of the
tudies included in the present meta-analysis, any known
nd unknown confounders of stent thrombosis should be
ivided equivalently between both arms of the study.
A large percentage of enrolled participants eventually
nderwent angiographic follow-up. In six of the studies,
epeat angiography was performed in approximately 80% to
early 100% of participants. Angiographic follow-up was
ower in the DELIVER-I and TAXUS-IV trials, where
nly 42% and 56% of participants, respectively, underwent
ollow-up angiography. It remains possible that these an-
iographic subsets are not representative of the entire group
f participants, although there was no indication of in-
reased mortality or myocardial infarction in either group
uring longer periods of clinical follow-up. This is sup-
orted by a recent meta-analysis that analyzed sirolimus-
luting stents and PES compared to BMS. This analysis
ound that all-cause mortality and myocardial infarction
ere not increased by the use of DES, (odds ratiomortality 
.11, 95% CI 0.61 to 2.06; odds ratiomyocardial infarction 
.92, 95% CI 0.65 to 1.25) (23). Additionally, none of the
nalyzed trials commented upon discovering a clinically
ilent occluded target vessel at the time of protocol-driven
ngiography. Because it is unclear if these events occurred
and if they did, whether or not they were tabulated as a
hrombotic event), then another source of potential bias
xists.
We also included any occurrence of thrombosis during
ollow-up including periprocedural thrombotic events.
eriprocedural myocardial infarctions were not included for
nalysis unless the investigators felt that the event was
econdary to stent thrombosis. It is possible that periproce-
ural thrombi are more influenced by technical aspects of
he stent-based PCI (such as coronary dissection or under-
eployment of the stent), rather than effects of the drug
tself. While this might be true, there were only three
ccurrences of periprocedural stent-associated thrombi (one
n the PES arm and two in the BMS arms), thus minimiz-
ng the importance of this potential effect.
So although there is some anecdotal concern that DES
ay increase the hazard of stent thrombosis, the current
tudy supplements available experimental and clinical evi-
ence to suggest that thrombosis does not occur more (oress) frequently than with BMS. Additionally, it remainsossible that in real word practice, if adequate oral anti-
latelet therapy is not used or prematurely discontinued
fter revascularization, the hazard of stent thrombosis with
ES may be greater than with BMS.
eprint requests and correspondence: Dr. Deepak L. Bhatt,
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and Clinic Foundation, Department of Cardiovascular Medicine,
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